Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Azapirones: history of development.

¹CNS Special Projects, Bristol-Myers Squibb Company, Wallingford, CT 06492-7660.

Journal of Clinical Psychopharmacology

|June 1, 1990

Summary

Azapirones, like buspirone, show promise as antidepressants and anxiolytics by targeting serotonin 5-HT1A receptors. This new drug class may offer mood disorder treatment with fewer side effects than older medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·1999

Same author

Characterization of melatonin-induced fos-like immunoreactivity in the hypothalamic suprachiasmatic nucleus of the rat.

Journal of receptor and signal transduction research·1999

Same author

Melatonin agonists induce phosphoinositide hydrolysis in Xenopus laevis melanophores.

Cellular signalling·1997

Same author

Regulation of central 5-HT2A receptors: a review of in vivo studies.

Behavioural brain research·1996

Same author

Melatonin agonists modulate 5-HT2A receptor-mediated neurotransmission: behavioral and biochemical studies in the rat.

The Journal of pharmacology and experimental therapeutics·1995

Same author

Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.

The Journal of clinical psychiatry·1995

Area of Science:

Pharmacology
Neuroscience
Psychiatry

Background:

The evolution of anxiety treatments has progressed from less selective agents to more specific drugs like benzodiazepines.
Buspirone, an azapirone, was approved in 1986, heralding a new phase in psychotherapeutic drug development.

Observation:

Azapirones, including buspirone and gepirone, represent a distinct pharmacologic class.
These drugs exhibit a unique affinity for the serotonin (5-hydroxytryptamine [5-HT]) type 1A (5-HT1A) receptor subtype.

Findings:

The specific affinity for the 5-HT1A receptor is believed to be responsible for the therapeutic effects of azapirones.
Evidence suggests that this new generation of anxiolytic drugs may possess antidepressant potential.

Implications:

Azapirones offer the potential for effective mood disorder therapy.
Their distinctive characteristics may lead to treatments with fewer adverse effects compared to existing options like benzodiazepines.

Related Experiment Videos